The Company’s current investors include:

Abingworth Management
www.abingworth.com

Cancer Research Ventures
www.cancertechnology.com

Essex Woodlands Healthcare Ventures
www.essexwoodlands.com

Gilde Investment Management
www.gilde.nl

Nomura Phase4 Ventures
www.nomura.com/npv

The Institute of Cancer Research
www.icr.ac.uk

The University of Cambridge
www.cam.ac.uk

The Wellcome Trust
www.wellcome.ac.uk

Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797

Cell Accumulation Approach